HSBC Holdings
NMRA icon

HSBC Holdings’s Neumora Therapeutics NMRA Stock Holding History

HSBC Holdings’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.8K Hold
11,387
– – ﹤0.01% 2896
2026
Q1 		$22.7K Sell
11,387
-3,573
-24% -$9.26K ﹤0.01% 2856
2025
Q4 		$26.9K Buy
+14,960
New +$32.8K ﹤0.01% 2892
2024
Q4 		– Sell
-10,067
Closed -$133K – 3194
2024
Q3 		$133K Buy
+10,067
New +$117K ﹤0.01% 2739

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HSBC Holdings's NMRA Position: Q2 2026 in Review

HSBC Holdings held its Neumora Therapeutics (NMRA) position steady in Q2 2026 at 11,387 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2896.

HSBC Holdings first reported a position in NMRA in Q3 2024 and has held it in 4 quarters since. The position peaked at $133K in Q3 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • HSBC Holdings held 11,387 shares of Neumora Therapeutics worth $19.8K as of Q2 2026.
  • HSBC Holdings left its Neumora Therapeutics share count unchanged in Q2 2026.
  • Neumora Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2896 holding.
  • HSBC Holdings first reported a position in Neumora Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • HSBC Holdings's Neumora Therapeutics position peaked at $133K in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.